José Aguado to Treatment Outcome
This is a "connection" page, showing publications José Aguado has written about Treatment Outcome.
Connection Strength
0.106
-
Effectiveness of anakinra for tocilizumab-refractory severe COVID-19: A single-centre retrospective comparative study. Int J Infect Dis. 2021 Apr; 105:319-325.
Score: 0.033
-
A short course of antibiotic treatment is safe after catheter withdrawal in catheter-related bloodstream infections due to coagulase-negative staphylococci. Eur J Clin Microbiol Infect Dis. 2019 May; 38(5):977-983.
Score: 0.029
-
Risk factors for unfavorable outcome and impact of early post-transplant infection in solid organ recipients with COVID-19: A prospective multicenter cohort study. PLoS One. 2021; 16(4):e0250796.
Score: 0.008
-
Tocilizumab use in Kidney Transplant Patients with COVID-19. Clin Transplant. 2020 11; 34(11):e14072.
Score: 0.008
-
Varied clinical presentation and outcome of SARS-CoV-2 infection in liver transplant recipients: Initial experience at a single center in Madrid, Spain. Transpl Infect Dis. 2020 Oct; 22(5):e13372.
Score: 0.008
-
Extended-pulsed fidaxomicin versus vancomycin in patients 60 years and older with Clostridium difficile infection: cost-effectiveness analysis in Spain. Eur J Clin Microbiol Infect Dis. 2019 Jun; 38(6):1105-1111.
Score: 0.007
-
Tuberculosis Recommendations for Solid Organ Transplant Recipients and Donors. Transplantation. 2018 02; 102(2S Suppl 2):S60-S65.
Score: 0.007
-
Initial use of echinocandins does not negatively influence outcome in Candida parapsilosis bloodstream infection: a propensity score analysis. Clin Infect Dis. 2014 May; 58(10):1413-21.
Score: 0.005